[go: up one dir, main page]

AR008838A1 - Nuevo tratamiento. - Google Patents

Nuevo tratamiento.

Info

Publication number
AR008838A1
AR008838A1 ARP970104238A ARP970104238A AR008838A1 AR 008838 A1 AR008838 A1 AR 008838A1 AR P970104238 A ARP970104238 A AR P970104238A AR P970104238 A ARP970104238 A AR P970104238A AR 008838 A1 AR008838 A1 AR 008838A1
Authority
AR
Argentina
Prior art keywords
pain
neuralgia
diseases
treatment
new treatment
Prior art date
Application number
ARP970104238A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR008838A1 publication Critical patent/AR008838A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Derivados y Análogos de benzopirano se describen como utiles para el tratamiento y/o la profilaxis de enfermedades degenerativas tales como corea deHuntingdon, esquizofrenia, déficit neurologicos asociados con el SIDA, trastornos delsueno (incluídos trastornos del ritmo circadiano, insomnio ynarcolepsia), tics (por ejemplo síndrome de Giles de la Tourette), lesion traumática del cerebro, zumbido, neuralgia, especialmente neuralgia trigémina,dolor neuropático, dolordental, dolor de cancer, actividad nuronal inapropiada que resulta en una neurodistesia en enfermedades tales como diabetes, EM, y laenfermedad de la neurona motora, ataxias, rigidez muscular (espasmos) y disfuncion de la uniontémporo-mandibular.
ARP970104238A 1996-09-18 1997-09-16 Nuevo tratamiento. AR008838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619492.3A GB9619492D0 (en) 1996-09-18 1996-09-18 Novel treatment

Publications (1)

Publication Number Publication Date
AR008838A1 true AR008838A1 (es) 2000-02-23

Family

ID=10800127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104238A AR008838A1 (es) 1996-09-18 1997-09-16 Nuevo tratamiento.

Country Status (30)

Country Link
EP (1) EP0939630B1 (es)
JP (1) JP2001500520A (es)
KR (1) KR20000036184A (es)
CN (1) CN1230885A (es)
AP (1) AP9901473A0 (es)
AR (1) AR008838A1 (es)
AT (1) ATE270102T1 (es)
AU (1) AU730465B2 (es)
BG (1) BG103252A (es)
BR (1) BR9712030A (es)
CA (1) CA2266681A1 (es)
DE (1) DE69729735T2 (es)
DZ (1) DZ2311A1 (es)
EA (1) EA199900306A1 (es)
ES (1) ES2223075T3 (es)
GB (1) GB9619492D0 (es)
HU (1) HUP9904638A3 (es)
ID (2) ID23175A (es)
IL (1) IL128786A0 (es)
MA (1) MA24321A1 (es)
NO (1) NO991292L (es)
NZ (1) NZ334271A (es)
OA (1) OA10998A (es)
PE (1) PE109898A1 (es)
PL (1) PL332313A1 (es)
SK (1) SK35199A3 (es)
TR (1) TR199900527T2 (es)
UY (1) UY24717A1 (es)
WO (1) WO1998011890A1 (es)
ZA (1) ZA978359B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
CA2726874A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
EP2307004A1 (en) * 2008-06-05 2011-04-13 Minster Research Limited Novel treatments
NZ598942A (en) 2009-07-27 2014-02-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN102970991A (zh) * 2009-12-03 2013-03-13 普罗克西梅根有限公司 异常性疼痛和痛觉增敏的治疗
CN102770134A (zh) * 2009-12-03 2012-11-07 普罗克西梅根有限公司 传染性失调的治疗
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112721D0 (en) * 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
US5510375A (en) * 1993-11-19 1996-04-23 Warner-Lambert Company Coumarin derivatives as protease inhibitors and antiviral agents
GB9411635D0 (en) * 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
CN1234702C (zh) * 1994-06-10 2006-01-04 史密丝克莱恩比彻姆有限公司 苯并吡喃类化合物和包含它们的药物组合物

Also Published As

Publication number Publication date
DZ2311A1 (fr) 2002-12-28
NZ334271A (en) 2001-03-30
ZA978359B (en) 1999-03-17
CA2266681A1 (en) 1998-03-26
MA24321A1 (fr) 1998-04-01
ID23175A (id) 2000-03-23
AP9901473A0 (en) 1999-03-31
KR20000036184A (ko) 2000-06-26
PL332313A1 (en) 1999-08-30
PE109898A1 (es) 1999-03-21
DE69729735T2 (de) 2005-07-14
UY24717A1 (es) 2001-08-27
JP2001500520A (ja) 2001-01-16
BR9712030A (pt) 1999-08-24
HUP9904638A3 (en) 2001-08-28
TR199900527T2 (xx) 1999-06-21
AU4704797A (en) 1998-04-14
EA199900306A1 (ru) 1999-08-26
EP0939630A1 (en) 1999-09-08
ES2223075T3 (es) 2005-02-16
AU730465B2 (en) 2001-03-08
CN1230885A (zh) 1999-10-06
GB9619492D0 (en) 1996-10-30
BG103252A (en) 1999-09-30
OA10998A (en) 2003-03-04
IL128786A0 (en) 2000-01-31
NO991292D0 (no) 1999-03-17
SK35199A3 (en) 2000-07-11
WO1998011890A1 (en) 1998-03-26
HUP9904638A2 (hu) 2001-05-28
EP0939630B1 (en) 2004-06-30
ATE270102T1 (de) 2004-07-15
DE69729735D1 (de) 2004-08-05
NO991292L (no) 1999-03-17
ID19542A (id) 1998-07-23

Similar Documents

Publication Publication Date Title
AR008838A1 (es) Nuevo tratamiento.
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE214903T1 (de) Verwendung von perfluorkohlenwasserstoffen zur herstellung von potenzierungsmitteln für die ultraschallvermittelte hyperthermiebehandlung von biologischen geweben
WO2004060146A3 (en) Method of treatment for central nervous system injury
IL191068A0 (en) Apparatus for treating neurological disorders by means of chronic adaptive brain stimulation as a function of local biopotentials
ES2082887T3 (es) Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
DE69827513D1 (de) Anordnung zur behandlung von neurodegenerativen störungen mittels infusion von nervenwachstumsfaktoren in das gehirn
WO2007061750A3 (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
ZA95884B (en) Chloropyrimidine intermediates
DE60142236D1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
EP0533585B1 (en) Apparatus for regulating and improving the status of development and survival of living organisms
GT200000203A (es) Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
WO2002066469A3 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
ES2150021T3 (es) Derivados de acidos piridin- y pirazin-dicarboxilicos como reguladores de la proliferacion celular.
US20210186803A1 (en) Vibratory infrared oligodynamic apparatus and musculoskeletal pain treatment method using same
ES2134709A1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
WO2000061231A3 (en) Medical use
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
ECSP972256A (es) Nuevo tratamiento y/o profilaxis de enfermedades degenerativas
IL164779A0 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders
RU94006635A (ru) Способ коррекции функциональных состояний
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal